The Biomarkers Consortium’s Cancer, Inflammation & Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview.

The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

See below for the membership of each Biomarkers Consortium Steering Committee:

  Cancer Steering Committee

Gary Kelloff, M.D., NIH/NCI , (Co-Chair)
Eric Rubin, M.D., Merck (Co-Chair)
Lukas Amler, Ph.D., Genentech
Daniel Auclair, Ph.D., The Multiple Myeloma Research Foundation
Steve Averbuch, M.D., Bristol-Myers-Squibb
J. Carl Barrett, M.D., AstraZeneca
Donald A. Berry, Ph.D., MD Anderson Cancer Center
Anahita Bhathena, Ph.D., AbbVie
Gideon Blumenthal, M.D., FDA/CDER
Khaled Bouri, Ph.D., M.P.H., FDA/OC
Lisa Butterfield, Ph.D., Society for Immunotherapy of Cancer
Claudio Carini, M.D., Ph.D., Oxford Biodynamics
David Chang, M.D., Ph.D., Kite Pharma, Inc.
Michele Cleary, Ph.D., BMS
Allison M. Cushman-Vokoun, M.D., Ph.D., University of Nebraska
Ajeeta Dash, Ph.D., Takeda Pharmaceuticals International, Inc.
Gregory Friberg, M.D., Amgen
Steve Gutman, M.D., Illumina
Stanley R. Hamilton, M.D., MD Anderson Cancer Center
Jon Heimer, Ph.D., Olink Proteomics
Steffan Ho, M.D., Ph.D., Pfizer
Karl Hsu, M.D., Sanofi
Robert Iannone, M.D., AstraZeneca
Jonathan Jarow, M.D., FDA/CDER
Jon Jessup, M.D., Inova
David Kaufman, M.D., Ph.D., Merck
Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies
Sam LaBrie, Ph.D., Myriad RBM
Jerry Lee, Ph.D., NIH/NCI/OVP
Robert McCormack, Ph.D., Janssen (JNJ)
Helen Moore, Ph.D., NIH/NCI
Larry Nagahara, Ph.D., John’s Hopkins University
Michael O’Neal, M.D., BioClinica, Inc.
Jim Pannucci, Ph.D.,Frederick Natl. Lab. For Cancer Research
David R. Parkinson, M.D., Essa Pharmaceuticals
Gregory Reaman, M.D., FDA/CDER
Henry Rodriguez, Ph.D., NIH/NCI
Andrew E. Schade, M.D., Ph.D., Eli Lilly & Company
Mitchell Schnall, M.D., Ph.D., University of Pennsylvania
Lawrence Schwartz, M.D., Columbia University
Ellen V. Sigal, Ph.D., Friends of Cancer Research
Daniel C. Sullivan, M.D., Duke University
Nancy Valente, M.D., Genentech
Wolfgang Weber, M.D., Memorial Sloan Kettering
Mickey Williams, Ph.D., NIH/NCI

  Inflammation & Immunity Steering Committee

David Fox, M.D., University of Michigan (Co-Chair)
David Chang, M.D., M.P.H, F.A.C.R., AstraZeneca (Co-Chair)
Robert Benschop, Ph.D., Eli Lilly
Maria Bettinotti, Ph.D., Association for Molecular Pathology
Anita Boyapati, Ph.D., Regeneron
Carrie Brodmerkel, Ph.D., Janssen (JNJ)
Katherine Call, Ph.D., Genzyme (Sanofi)
Claudio Carini, M.D., Ph.D., Oxford Biodynamics
James Chung, M.D., Amgen
B. Melina Cimler, Ph.D., Adaptive Biotechnologies
Carolyn Cuff, Ph.D., AbbVie
Mark Curran, Ph.D., Janssen (JNJ)
Sean Curtis, M.D., Merck
Sahar M. Dawisha, M.D., FDA/CDRH
Betty Diamond, Ph.D., Feinstein Institute
Guy Eakin, Ph.D., Arthritis Foundation
Thomas Fuerst, Ph.D., BioClinica
Kristie M. Grebe, Ph.D, AbbVie
Jennifer Hall, Ph.D., American Heart Association
Martin Hodge, Ph.D, Pfizer
Kathy Jung, Ph.D.,  NIH/NIAA
Bruce Littman, M.D., Portage Pharmaceuticals Ltd.
Bruce McManus, M.D., Ph.D., University of British Columbia
Devangi Mehta, Ph.D., Biogen
Jordan Pober, M.D., Ph.D., Yale University
Barbara Radziszewska, Ph.D., M.P.H., NIH/NIA
Mahboob Rahman, M.D., Ph.D., Novartis
Koustubh Ranade, Ph.D., Medimmune (AstraZeneca)
Narges Rashidi, Ph.D., OLINK
John Reveille, M.D., University of Texas Health Science Center (Houston)
Lisa Rider, M.D., NIH/NIEHS
Dan Rotrosen, M.D., NIH/NIAID
Jane Salmon, M.D., Hospital for Special Surgery
Linda Sandell, Ph.D., Washington University, St. Louis (OARSI).
Susana A. Serrate-Sztein, M.D., NIH/NIAMS
Glennda Smithson, Ph.D., Takeda
Lisa M. Spain, Ph.D., NIH/ NIDDK
Giorgio Trinchieri, M.D., NIH/ NCI
Ursula Utz, MBA, Ph.D., NIH/ NINDS
Sanya Fanous Whitaker, Ph.D., PMP, Fredrick National Laboratory for Cancer Research

  Metabolic Disorders Steering Committee

Myrlene Staten, M.D., NIH/NIDDK (Co-Chair)
Roberto Calle, M.D., Pfizer (Co-Chair)
Patricia Andrade-Gordon, Ph.D., Janssen (JNJ)
Harold Bernsein, M.D., Ph.D., Merck
Carlos Blanco, M.D., Ph.D., NIH/NIDA
Tamara Darsow, Ph.D., ADA
Klaus Engelke, Ph.D., BioClinica
David Fryburg, M.D., ROI BioPharma Consulting
Jean-Marc Guettier, M.D., FDA/CDER
Saurabh Gupta, Ph.D., Takeda
Jennifer Hall, M.D., The American Heart Association
Judy Hannah, Ph.D., NIH/NIA
Joyce Harp, M.D., Regeneron
Boaz Hirschberg, M.D., AstraZeneca
Claude Hughes, M.D., Ph.D., Quintiles
Teresa L. Jones, M.D., NIH/ NIDDK
Lyndon Joseph, Ph.D., NIH/NIA
Helina Kassahun, M.D., Amgen
David Kelley, M.D., Merck
Young S. Kim, Ph.D., NIH/NCI
Paul Kimmel, M.D., NIH/NIDDK
Martin Lorenz, M.D., Sanofi
Rong Mao, M.D., The Association for Molecular Pathology
James Mapes, Ph.D., Myriad RBM
Frank Martin, Ph.D., JDRF
John W. Newcomer, M.D., Florida Atlantic University
Maria-Magdalena Petru, M.D., Ortho Clinical Diagnostics
Bruce S. Schneider, M.D., FDA/CBER
Sudha Shankar, M.D., Eli Lilly and Company
Robert Sherwin, M.D., Yale University
Michelle Slimko, M.P.H., R.D., National Dairy Council
Pothur Srinivas, Ph.D., NIH/NHLBI
Elizabeth Stafford, Ph.D., FDA/CDRH
Robert Umek, Ph. D., MesoScale Diagnostics
David R. Vera, Ph.D., University of California, San Diego
Jessica Williams, J.D. SomaLogic

  Neuroscience Steering Committee

Linda Brady, Ph.D., NIH/NIMH (Co-Chair)
Husseini K. Manji, M.D., J&J (Co-Chair)
William Potter, M.D., Ph.D., NIH/NIMH/OD (Co-Chair Emeritus)
Huda Akil, Ph.D., M.A., UMich (Co-Chair Emeritus)
Rita Balice-Gordon, Ph.D., Sanofi
Daniel Barboriak, M.D., RSNA
Wade Berrettini, M.D., Ph.D., UPenn
Silvana Borges, M.D., FDA
Claudio Carini, M.D., Ph.D., Oxford Biodynamics
Maria Carrillo, Ph.D., Alzheimer's Association
Caroline Cohen, Ph.D., Sanofi
Susan Croll, Ph.D., Regeneron
Thomas P. Finn, Ph.D., FDA/CBER
Mark Forman, M.D., Ph.D., Merck
Mark Frasier, Ph.D., Michael J. Fox Foundation
Danielle Graham, Ph.D., Biogen Idec
James Hendrix, Ph.D., Alzheimer’s Association
M. Katherine Jung, Ph.D., NIH/NIAAA
Walter J. Koroshetz, M.D., NIH/NINDS
Frank Lebeda, Ph.D., U.S. Military
Eliezer Masliah, Ph.D., (NIH/NIA)
Bradley Miller, M.D., Ph.D., Lilly
Niels Plath, Ph.D., Lundbeck
Stephane Pollentier, M.D., Boehringer-Ingelheim
Sounder Regunathan, Ph.D., NIH/NIAAA
Cristina Sampaio, M.D., Ph.D., CHDI
Steve Sands, Ph.D., Amgen
Darryl Schoepp, Ph.D., Merck & Co.
Howard Schulman, Ph.D., Allosteros Therapeutics
Michael Spain, M.D., Myriad RBM
Holly Soares, Ph.D., Abbvie
Joyce Suhy, Ph.D., BioClinica
Marg Sutherland, Ph.D., NIH/NIMH
Johannes Tauscher, M.D., Takeda
Chris Turck, Ph.D., Max Planck Institute of Psychiatry
Robert Umek, Ph.D., Meso Scale Discovery
Gabriel Vargas, Ph.D., Amgen

 

Front Page: